YolTech Kicks Off First-In-Class In Vivo Gene Editing Trial For TDT

Other Chinese Firms Build Presence In Field

YolTech’s early clinical stage in vivo gene editing therapy YOLT-204 may provide off-the-shelf treatment in transfusion dependent β-thalassemia without conditioning chemotherapy and HSCT.

Gene editing tool
YolTech Therapeutics' first-in-class in vivo gene editing therapy, YOLT-204, in transfusion dependent β-thalassemia recently entered clinical trial. (Shutterstock)

YolTech Therapeutics, a Shanghai-based start-up focusing on in vivo gene editing, recently announced the initiation of an early Phase I trial with YOLT-204, a first-in-class therapy, in transfusion dependent β-thalassemia (TDT).

Xu Hu

Read more by Xu Hu

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

More from Clinical Trials

Almirall CEO Alarm Over Europe’s Reduced Competitiveness

 
• By 

The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By 

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

Cassava At Crossroads As Simufilam Finally Exits, Stage Left

 

The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.

Sanofi Nabs Priority Review For MS Drug Tolebrutinib

 
• By 

A decision from the FDA is due by 28 September.

More from Focus On Asia

Profile: Anil Koul’s Journey From ‘Jumping Genes’ To Sirturo And AI-Led Drug Discovery

 

Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.

AstraZeneca Expands Emphasis On China, Already A Key Market

 
• By 

UK pharma will invest $2.5bn in Beijing R&D hub, build a vaccine manufacturing site with BioKangtai, and partner in chronic disease with Syneron and in oncology/immunology with Harbour BioMed.

Korea Needs To Think Bigger On M&As: KHIDI

 

A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.